Protara Therapeutics Inc. (TARA)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
4.70
-0.33 (-6.56%)
At close: Jan 15, 2025, 3:59 PM
4.58
-2.55%
After-hours Jan 15, 2025, 05:48 PM EST
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 2.95M | n/a | n/a |
Cost of Revenue | 341.00K | 247.00K | 1.17M | 196.00K | 16.00K | 115.00K | 148.00K | 123.00K | 57.00K | n/a | 27.00K | 57.00K |
Gross Profit | -341.00K | -247.00K | -1.17M | -196.00K | -16.00K | -115.00K | -148.00K | -123.00K | -57.00K | 2.95M | -27.00K | -57.00K |
Operating Income | -43.61M | -67.06M | -47.49M | -34.44M | -15.25M | -26.08M | -30.36M | -28.70M | -20.87M | -7.58M | -7.12M | -8.00M |
Interest Income | 2.73M | 1.11M | 237.00K | 466.00K | n/a | n/a | n/a | n/a | n/a | n/a | 4.00K | 20.00K |
Pretax Income | -40.42M | -65.95M | -47.25M | -33.98M | -14.99M | -25.44M | -29.96M | -28.53M | -21.38M | -3.34M | -7.91M | -7.97M |
Net Income | -40.42M | -64.81M | -47.13M | -33.51M | -14.73M | -25.44M | -29.96M | -28.53M | -21.38M | -3.34M | -7.91M | -7.97M |
Selling & General & Admin | 18.62M | 20.74M | 26.40M | 22.46M | 8.82M | 10.57M | 8.53M | 9.71M | 8.43M | 4.10M | 3.10M | 2.03M |
Research & Development | 24.79M | 16.81M | 21.09M | 11.98M | 6.44M | 15.51M | 21.69M | 18.87M | 12.38M | 6.43M | 3.99M | 5.91M |
Other Expenses | n/a | 29.52M | n/a | n/a | n/a | 207.00K | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 43.61M | 37.55M | 47.49M | 34.44M | 15.25M | 26.08M | 30.21M | 28.58M | 20.81M | 10.53M | 7.09M | 7.94M |
Interest Expense | n/a | 1.14M | 1.74M | 34.00K | n/a | n/a | 259.00K | 193.00K | 144.00K | 857.00K | 861.00K | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | 8.42M | -123.00K | -57.00K | n/a | n/a | n/a |
Cost & Expenses | 43.61M | 37.55M | 47.49M | 34.44M | 15.25M | 26.08M | 30.36M | 28.70M | 20.87M | 10.53M | 7.12M | 8.00M |
Income Tax | n/a | -1.14M | -117.00K | -466.00K | -262.00K | 5.35M | 657.00K | 372.00K | -363.00K | 5.09M | n/a | n/a |
Shares Outstanding (Basic) | 11.33M | 11.26M | 11.23M | 7.23M | 64.44K | 2.56M | 431.86K | 414.04K | 411.60K | 76.61K | 374.85K | 374.85K |
Shares Outstanding (Diluted) | 11.33M | 11.26M | 11.23M | 7.23M | 64.44K | 2.56M | 431.86K | 414.04K | 411.60K | 76.61K | 374.85K | 374.85K |
EPS (Basic) | -3.57 | -5.76 | -4.2 | -4.63 | -228.6 | -9.93 | -69.38 | -68.9 | -51.94 | -43.62 | -37.43 | -37.62 |
EPS (Diluted) | -3.57 | -5.76 | -4.2 | -4.63 | -228.6 | -9.93 | -69.38 | -68.9 | -51.94 | -43.62 | -37.43 | -37.62 |
EBITDA | -43.27M | -64.57M | -46.09M | -33.78M | -7.81M | -20.61M | -29.82M | -28.40M | -21.32M | -2.45M | -7.02M | -7.91M |
Depreciation & Amortization | 341.00K | 247.00K | 1.17M | 196.00K | 16.00K | 115.00K | 148.00K | 123.00K | 57.00K | 30.00K | 27.00K | 57.00K |